...
Dataset wrap |
---|
|
Rowcaps |
---|
Rows 7-8: | Show the identification of a split tumor when it was first identified as split (fragmented). In this example, TULNKID = "tumor T04 " splits into 2 tumors TULNKID = "(T04.1" and TULNKID = ", T04.2" with TUGRPID = "T04". ); TUGRPID = "T04" provides traceability and links the split tumor to its parent recordsrecord. | Row 9: | Shows the identification of a merged tumor when it was first identified as merged (coalesced). In this example, TULNKID = "tumors T02 " and TULNKID = " T03 " merged into tumor T02/T03; TULNKID = "T02/T03" . The TULNKID is a combination of the child tumors and therefore provides the traceability back to the child tumors. |
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | TUSEQ | TUGRPID | TUREFID | TUSPID | TULNKID | TUTESTCD | TUTEST | TUORRES | TUSTRESC | TULOC | TUMETHOD | TUEVAL | EPOCH | VISITNUM | VISIT | TUDTC | TUDY |
---|
1 | EX22222 | TU | 90002 | 1 |
| IMG-00001 | TRG-SCR-01 | T01 | TUMIDENT | Tumor Identification | TARGET | TARGET | LUNG, RIGHT MIDDLE LOBE | CT SCAN | INVESTIGATOR | SCREEN | 1 | SCREENING | 2007-01-01 | 1 | 2 | EX22222 | TU | 90002 | 2 |
| IMG-00001 | TRG-SCR-02 | T02 | TUMIDENT | Tumor Identification | TARGET | TARGET | LUNG, LEFT LOWER LOBE | CT SCAN | INVESTIGATOR | SCREEN | 1 | SCREENING | 2007-01-01 | 1 | 3 | EX22222 | TU | 90002 | 3 |
| IMG-00001 | TRG-SCR-03 | T03 | TUMIDENT | Tumor Identification | TARGET | TARGET | LUNG, LEFT LOWER LOBE | CT SCAN | INVESTIGATOR | SCREEN | 1 | SCREENING | 2007-01-01 | 1 | 4 | EX22222 | TU | 90002 | 4 |
| IMG-00001 | TRG-SCR-04 | T04 | TUMIDENT | Tumor Identification | TARGET | TARGET | KIDNEY, UPPER LOBE | CT SCAN | INVESTIGATOR | SCREEN | 1 | SCREENING | 2007-01-01 | 1 | 5 | EX22222 | TU | 90002 | 5 |
| IMG-00001 | NTG-SCR-01 | NT01 | TUMIDENT | Tumor Identification | NON-TARGET | NON-TARGET | LUNG | CT SCAN | INVESTIGATOR | SCREEN | 1 | SCREENING | 2007-01-01 | 1 | 6 | EX22222 | TU | 90002 | 6 |
| IMG-00001 | NTG-SCR-02 | NT02 | TUMIDENT | Tumor Identification | NON-TARGET | NON-TARGET | LIVER | CT SCAN | INVESTIGATOR | SCREEN | 1 | SCREENING | 2007-01-01 | 1 | 7 | EX22222 | TU | 90002 | 7 | T04 | IMG-00002 | TRG-W16-07 | T04.1 | TUSPLIT | Tumor Split | TARGET | TARGET | KIDNEY, UPPER LOBE | CT SCAN | INVESTIGATOR | TREATMENT | 5 | WEEK 16 | 2007-04-24 | 112 | 8 | EX22222 | TU | 90002 | 8 | T04 | IMG-00002 | TRG-W16-08 | T04.2 | TUSPLIT | Tumor Split | TARGET | TARGET | KIDNEY, UPPER LOBE | CT SCAN | INVESTIGATOR | TREATMENT | 5 | WEEK 16 | 2007-04-24 | 112 | 9 | EX22222 | TU | 90002 | 9 |
| IMG-00003 | TRG-W28-07 | T02/T03 | TUMERGE | Tumor Merged | TARGET | TARGET | LUNG, LEFT LOWER LOBE | CT SCAN | INVESTIGATOR | TREATMENT | 7 | WEEK 24 | 2009-06-19 | 168 | 10 | EX22222 | TU | 90002 | 10 |
| IMG-00004 | NWT-W32-01 | NEW01 | TUMIDENT | Tumor Identification | NEW | NEW | LIVER | CT SCAN | INVESTIGATOR | TREATMENT | 9 | WEEK 32 | 2009-08-14 | 224 | |
|
...
4.3.3 TR Domain Model
The following tr.xpt table shows table shows the terminology used to implement RECIST implement RECIST 1.1 in the TR domain. This 1 in the TR domain. This example represents a situation where a result was not provided because the scan was not performed.
...
4.8.3 TR Domain Model
The following table shows table shows the terminology used to implement RECIST implement RECIST 1.1 in the TR domain1 in the TR domain. This example shows the data for 1 subject collected at the screening, week 12, and week 24 visits. This This example also shows that the tumor state for the non-target in the pleural cavity is an assessment of the pleural effusion. Scintigraphy of the bone was not required at every disease assessment per protocol. The The image identifier is in TRREFID.
...
Dataset wrap |
---|
|
Rowcaps |
---|
Rows 1-4: | Show the measurements of the "target tumor (R-T01" target tumor ) in the "LIVER" liver and the assessments of the 2 non-target lesions "(R-NT01" and ", R-NT02" ) in the "BONE" and "PLEURAL CAVITY" bone and pleural cavity at screening. | Rows 5-11: | Show the measurement of the "target tumor (R-T01" target tumor ) and the tumor state of the "1 non-target tumor (R-NT02" non-target ) in the "PLEURAL CAVITY" pleural cavity at week 12. In the Per protocol, "SCINTIGRAPHY" is scintigraphy was only to be performed every 6 months or in order to verify a CR (Complete Response). Therefore, the "SCINTIGRAPHY" of "complete response; therefore, scintigraphy of non-target R-NT01 " non-target in the "BONE" bone was not performed at week 12 (TRSTAT = "NOT DONE" and TRREASND = "SCAN NOT PERFORMED"). | Rows 12-18: | Show that, at week 24, the "target lesion (R-T01" target lesion ) was absent (i.e., DIAMETER = "0") and the ; non-targets R-"NT01 " and " R-NT02 " in the "BONE" and "PLEURAL CAVITY" also were absent (TRTESTCD = "TUMSTATE" with TRORRES = "ABSENT"). The "SCINTIGRAPHY" Scintigraphy was performed in order to verify the Overall Response overall response of CR (Complete Response). |
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | TRSEQ | TRGRPID | TRREFID | TRLNKGRP | TRLNKID | TRTESTCD | TRTEST | TRORRES | TRORRESU | TRSTRESC | TRSTRESN | TRSTRESU | TRSTAT | TRREASND | TRNAM | TRMETHOD | TREVAL | TREVALID | EPOCH | VISITNUM | VISIT | TRDTC | TRDY |
---|
1 | EX88888 | TR | 90008 | 1 | TARGET | IMG-00001 | R-A1 | R-T01 | LDIAM | Longest Diameter | 17 | mm | 17 | 17 | mm |
|
| VENDOR1 | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 2 | EX88888 | TR | 90008 | 2 | TARGET |
| R-A1 |
| SUMDIAM | Sum of Diameter | 17 | mm | 17 | 17 | mm |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 3 | EX88888 | TR | 90008 | 3 | NON-TARGET | IMG-00002 | R-A1 | R-NT01 | TUMSTATE | Tumor State | PRESENT |
| PRESENT |
|
|
|
| VENDOR1 | SCINTIGRAPHY | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-01 | -3 | 4 | EX88888 | TR | 90008 | 4 | NON-TARGET | IMG-00001 | R-A1 | R-NT02 | TUMSTATE | Tumor State | PRESENT |
| PRESENT |
|
|
|
| VENDOR1 | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 5 | EX88888 | TR | 90008 | 5 | TARGET | IMG-00004 | R-A2 | R-T01 | LDIAM | Longest Diameter | 7 | mm | 7 | 7 | mm |
|
| VENDOR1 | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 6 | EX88888 | TR | 90008 | 6 | TARGET |
| R-A2 |
| SUMDIAM | Sum of Diameter | 7 | mm | 7 | 7 | mm |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 7 | EX88888 | TR | 90008 | 7 | TARGET |
| R-A2 |
| ACNSD | Absolute Change From Nadir in Sum of Diameter | -10 | mm | -10 | -10 | mm |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 8 | EX88888 | TR | 90008 | 8 | TARGET |
| R-A2 |
| PCBSD | Percent Change From Baseline in Sum of Diameter | -59 | % | -59 | -59 | % |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 9 | EX88888 | TR | 90008 | 9 | TARGET |
| R-A2 |
| PCNSD | Percent Change From Nadir in Sum of Diameter | -59 | % | -59 | -59 | % |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 10 | EX88888 | TR | 90008 | 10 | NON-TARGET |
| R-A2 | R-NT01 | TUMSTATE | Tumor State |
|
|
|
|
| NOT DONE | SCAN NOT PERFORMED | VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 11 | EX88888 | TR | 90008 | 11 | NON-TARGET | IMG-00004 | R-A2 | R-NT02 | TUMSTATE | Tumor State | PRESENT |
| PRESENT |
|
|
|
| VENDOR1 | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 12 | EX88888 | TR | 90008 | 12 | TARGET | IMG-00005 | R-A3 | R-T01 | LDIAM | Longest Diameter | 0 | mm | 0 | 0 | mm |
|
| VENDOR1 | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | 13 | EX88888 | TR | 90008 | 13 | TARGET |
| R-A3 |
| SUMDIAM | Sum of Diameter | 0 | mm | 0 | 0 | mm |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 |
|
| 14 | EX88888 | TR | 90008 | 14 | TARGET |
| R-A3 |
| ACNSD | Absolute Change From Nadir in Sum of Diameter | -17 | mm | -17 | -17 | mm |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 |
|
| 15 | EX88888 | TR | 90008 | 15 | TARGET |
| R-A3 |
| PCBSD | Percent Change From Baseline in Sum of Diameter | -100 | % | -100 | -100 | % |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 |
|
| 16 | EX88888 | TR | 90008 | 16 | TARGET |
| R-A3 |
| PCNSD | Percent Change From Nadir in Sum of Diameter | -100 | % | -100 | -100 | % |
|
| VENDOR1 |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 |
|
| 17 | EX88888 | TR | 90008 | 17 | NON-TARGET | IMG-00006 | R-A3 | R-NT01 | TUMSTATE | Tumor State | ABSENT |
| ABSENT |
|
|
|
| VENDOR1 | SCINTIGRAPHY | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-24 | 172 | 18 | EX88888 | TR | 90008 | 18 | NON-TARGET | IMG-00005 | R-A3 | R-NT02 | TUMSTATE | Tumor State | ABSENT |
| ABSENT |
|
|
|
| VENDOR1 | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | |
|
4.8.4 PR Domain Model
The pr.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in 1 in the PR domainPR domain. This example shows the data for one 1 subject collected at the screening, week 12, and week 24 visits. Per Per protocol, non-target lesions in the "BONE" are assessed using "SCINTIGRAPHY" bone were assessed using scintigraphy as the primary method of assessment for RECIST 1.1. Correlative imaging is was used in addition to the primary method for the RECIST 1.1 evaluation in order to more closely assess the bone lesion(s). The primary method of assessment (i.e., scintigraphy) is represented in TU and TR domains along with assessment results. Correlative imaging (e.g., MRI of the FEMURfemur) is represented only in the PR domain. Scintigraphy and the correlative imaging are were not required at every disease assessment per protocol. However, often times the correlative imaging is performed at every disease assessment timepoint because the same scans cover lesions that are assessed at every disease assessment timepoint. The image identifier is in PRREFID.
Dataset wrap |
---|
|
Rowcaps |
---|
Rows 1-3: | Show the scans performed at screening. The CT SCAN scan and SCINTIGRAPHY scintigraphy are the primary methods used to assess the target and non-target lesion for RECIST 1.1 and ; the results are in TU and TR. Row 3 shows the correlative imaging (i.e., MRI) of the bone lesion in the FEMURfemur. | Rows 4-6: | Show that the CT scan was performed (PROCCUR = "Y") and that the scintigraphy and MRI were not performed (PROCCUR = "N") at week 12. | Rows 7-9: | Show the scans performed at week 24. |
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | PRSEQ | PRREFID | PRLNKGRP | PRTRT | PRLOC | PRPRESP | PROCCUR | EPOCH | VISITNUM | VISIT | PRSTDTC | PRSTDY |
---|
1 | EX88888 | PR | 90008 | 1 | IMG-00001 | A1 | CT SCAN | MULTIPLE | Y | Y | SCREEN | 10 | SCREENING | 2010-01-01 | -3 | 2 | EX88888 | PR | 90008 | 2 | IMG-00002 | A1 | SCINTIGRAPHY | BONE | Y | Y | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 3 | EX88888 | PR | 90008 | 3 | IMG-00003 | A1 | MRI | FEMUR | Y | Y | SCREEN | 10 | SCREENING | 2010-01-03 | -1 | 4 | EX88888 | PR | 90008 | 4 | IMG-00004 | A2 | CT SCAN | MULTIPLE | Y | Y | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 5 | EX88888 | PR | 90008 | 5 |
| A2 | SCINTIGRAPHY | BONE | Y | N | TREATMENT | 20 | WEEK 12 |
|
| 6 | EX88888 | PR | 90008 | 6 |
| A2 | MRI | FEMUR | Y | N | TREATMENT | 20 | WEEK 12 |
|
| 7 | EX88888 | PR | 90008 | 7 | IMG-00005 | A3 | CT SCAN | MULTIPLE | Y | Y | TREATMENT | 30 | WEEK 24 | 2010-06-24 | 172 | 8 | EX88888 | PR | 90008 | 8 | IMG-00006 | A3 | SCINTIGRAPHY | BONE | Y | Y | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | 9 | EX88888 | PR | 90008 | 9 | IMG-00007 | A3 | MRI | FEMUR | Y | Y | TREATMENT | 30 | WEEK 24 | 2010-06-25 | 173 | |
|
The following supppr.xpt table below shows the data to represent the multiple locations covered by the CT SCAN. The Anatomical Location 1 and Anatomical Location 2 anatomical location supplemental qualifiers (QNAM = "PRLOC1" and QNAM = "PRLOC2") supplemental qualifiers are used and controlled terminology is available (LOC).
Dataset wrap |
---|
|
Rowcaps |
---|
Rows 1-2: | Show the 2 locations of the CT SCAN scan for PRSEQ = "1" where QNAM = "PRLOC1" with QVAL = "CHEST" and QNAM = "PRLOC2" with QVAL = "ABDOMEN". | Rows 3-6: | Show the 2 locations of the CT SCAN scan for PRSEQ 4 and 7. |
|
Dataset2 |
---|
Row | STUDYID | RDOMAIN | USUBJID | IDVAR | IDVARVAL | QNAM | QLABEL | QVAL | QORIG |
---|
1 | EX88888 | PR | 90008 | PRSEQ | 1 | PRLOC1 | Anatomical Location 1 | CHEST | eDC | 2 | EX88888 | PR | 90008 | PRSEQ | 1 | PRLOC2 | Anatomical Location 2 | ABDOMEN | eDC | 3 | EX88888 | PR | 90008 | PRSEQ | 4 | PRLOC1 | Anatomical Location 1 | CHEST | eDC | 4 | EX88888 | PR | 90008 | PRSEQ | 4 | PRLOC2 | Anatomical Location 2 | ABDOMEN | eDC | 5 | EX88888 | PR | 90008 | PRSEQ | 7 | PRLOC1 | Anatomical Location 1 | CHEST | eDC | 6 | EX88888 | PR | 90008 | PRSEQ | 7 | PRLOC2 | Anatomical Location 2 | ABDOMEN | eDC |
|
|
4.9 Example 9 Example 9: No Evidence of Disease at Baseline
RECIST 1.1 example to show This example shows an assessment where the independent radiologist found no evidence of disease at baseline.
4.9.1 RS Domain Model
The rs.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in 1 in the RS domainRS domain. This example shows the data collected for one 1 subject at screening for which ; the independent radiologist found no evidence of disease at baseline (RSSTRESC = "NED"). This a rare case where a response assessment would be recorded based on the screening assessment. RSCAT = "PROTOCOL DEFINED RESPONSE CRITERIA" was used to indicate that this result is not based on RECIST 1.1. In this example, there are no data in TU or TR, because no tumors were identified.
Dataset wrap |
---|
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | RSSEQ | RSLNKGRP | RSTESTCD | RSTEST | RSCAT | RSORRES | RSSTRESC | RSNAM | RSEVAL | RSEVALID | EPOCH | VISITNUM | VISIT | RSDTC | RSDY |
---|
1 | EX99999 | RS | 90009 | 1 | A1 | OVRLRESP | Overall Response | PROTOCOL DEFINED RESPONSE CRITERIA | NED | NED | RADIOL. INC. | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-03-29 | 1 | |
|
4.10 Example 10: Enlargement from Nadir of a Single Non-
...
target
This example shows
...
RECIST 1.1 example to show response (RS) data and the underlying tumor identification (TU) and tumor results (TR) data based on an independent independent assessment. This example shows the situation where In this situation, enlargement from nadir of a single Nonnon-target lesion/tumor does not necessarily mean necessarily mean that the Nonnon-Target Response is PDtarget response is progressive disease.
4.10.1 RS Domain Model
The rs.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in 1 in the RS domainRS domain. This example shows the data for one 1 subject collected at the week 12 and a subsequent 12-week follow-up visit.
Dataset wrap |
---|
Rowcaps |
---|
Rows 1-3: | Show the Target Response target response (RSTESTCD = "TRGRESP"), Nonnon-Target Response target response (RSTESTCD = "NTRGRESP"), and Overall Response overall response (RSTESTCD = "OVRLRESP") at week 12. The Target Response target response of PR (Partial Response) is based on the Percent Change From Baseline in Sum of Diameter percent change from baseline in sum of diameter (PCBSD) of -59%. The Nonnon-Target Response target response of SD (Stable Disease) is based on the judgement assessment of the non-target lesions/tumors taken collectively. In this case at week 12, one 1 of the non-targets is absent and one 1 of the non-targets has enlarged from nadir. The Overall Response overall response is PR (Partial Response). | Rows 4-6: | Show the Target Response (RSTESTCD = "TRGRESP"), Non-Target Response (RSTESTCD = "NTRGRESP") and Overall Response (RSTESTCD = "OVRLRESP") target response, non-target response, and overall response at week 24. The Target Response target response of CR (Complete Response) is based on the Percent Change From Baseline in Sum of Diameter ( PCBSD ) of -100%. The Nonnon-Target Response target response of SD (Stable Disease) is based on the judgement on assessment of the non-target lesions/tumors taken collectively. In this case at week 24, one 1 of the non-targets is absent and one 1 of the non-targets is still present. The Overall Response overall response is PR (Partial Response). |
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | RSSEQ | RSLNKGRP | RSTESTCD | RSTEST | RSCAT | RSORRES | RSSTRESC | RSNAM | RSEVAL | RSEVALID | EPOCH | VISITNUM | VISIT | RSDTC | RSDY |
---|
1 | EX01010 | RS | 90010 | 1 |
| TRGRESP | Target Response | RECIST 1.1 | PR | PR | RADIOL. INC. | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 2 | EX01010 | RS | 90010 | 2 |
| NTRGRESP | Non-Target Response | RECIST 1.1 | SD | SD | RADIOL. INC. | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 3 | EX01010 | RS | 90010 | 3 | R-A2 | OVRLRESP | Overall Response | RECIST 1.1 | PR | PR | RADIOL. INC. | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 4 | EX01010 | RS | 90010 | 4 |
| TRGRESP | Target Response | RECIST 1.1 | CR | CR | RADIOL. INC. | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | 5 | EX01010 | RS | 90010 | 5 |
| NRGRESP | Non-Target Response | RECIST 1.1 | SD | SD | RADIOL. INC. | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | 6 | EX01010 | RS | 90010 | 6 | R-A3 | OVRLRESP | Overall Response | RECIST 1.1 | PR | PR | RADIOL. INC. | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | |
|
4.10.2 TU Domain Model
The tu.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in the TU domain1 in the TU domain. This example shows the data for one 1 subject with target with target and non-target tumors identified at screening. The subject has 1 target lesion with (TULNKID = "R-T01") and 2 non-target lesions/sites with TULNKID "(R-NT01" and ", R-NT02" ) identified at screening. " T01 " and " R-NT01 " are located in the "LIVER" liver, and " R-NT02 " is located in the "CHEST WALL"chest wall.
Dataset wrap |
---|
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | TUSEQ | TULNKID | TUTESTCD | TUTEST | TUORRES | TUSTRESC | TUNAM | TULOC | TUMETHOD | TUEVAL | TUEVALID | EPOCH | VISITNUM | VISIT | TUDTC | TUDY |
---|
1 | EX01010 | TU | 90010 | 1 | R-T01 | TUMIDENT | Tumor Identification | TARGET | TARGET | RADIOL. INC. | LIVER | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 2 | EX01010 | TU | 90010 | 2 | R-NT01 | TUMIDENT | Tumor Identification | NON-TARGET | NON-TARGET | RADIOL. INC. | LIVER | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 3 | EX01010 | TU | 90010 | 3 | R-NT02 | TUMIDENT | Tumor Identification | NON-TARGET | NON-TARGET | RADIOL. INC. | CHEST WALL | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | |
|
4.10.3 TR Domain Model
The tr.xpt table below shows following table shows the terminology used to implement RECIST implement RECIST 1.1 in the TR domain1 in the TR domain. This example shows the data for one 1 subject collected at the screening, week 12, and subsequent 12-week follow-up visits.
This example shows the situation where the Independent Assessor independent assessor provided the summary values for Target target lesions as a group (TRGRPID = "TARGET"). The TRTESTCDs used for the assessments are: "SUMDIAM", "ACNSD", "PCBSD", and "PCNSD". Note that the sponsor sponsors should not derive these values if they were not part of the data capture or not provided in the transfer from the vendor.
Dataset wrap |
---|
|
Rowcaps |
---|
Rows 1-4: | Show the measurements of the " R-T01 " target tumor in the "LIVER" liver and the assessments of the 2 non-Target target lesions/sites " R-NT01 " and " R-NT02 " in the "LIVER" and "CHEST WALL" liver and chest wall at screening. | Rows 5-11: | Show the measurement of the "R-T01" target tumor and the tumor states of "R-NT01" and "R-NT02" the non-targets at week 12. " R-T01 " shows a decrease from 17mm at baseline to 7mm, which is a Percent Change From Baseline in Sum of Diameter ( PCBSD ) of -59%. " R-NT01 " has a TUMSTATE = "ABSENT" and "R-NT02" has a TUMSTATE = "ENLARGEMENT FROM NADIR". | Rows 12-18: | Show the measurement of the " R-T01 " target tumor and the tumor states of "R-NT01" and "R-NT02" the non-targets at week 24. " R-T01 " is absent (LDIAM = "0"), which is a Percent Change From Baseline in Sum of Diameter ( PCBSD ) of -100%. " R-NT01 " remains TUMSTATE = "ABSENT" and " R-NT02 " has a TUMSTATE = "PRESENT". |
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | TRSEQ | TRGRPID | TRLNKGRP | TRLNKID | TRTESTCD | TRTEST | TRORRES | TRORRESU | TRSTRESC | TRSTRESN | TRSTRESU | TRNAM | TRMETHOD | TREVAL | TREVALID | EPOCH | VISITNUM | VISIT | TRDTC | TRDY |
---|
1 | EX01010 | TR | 90010 | 1 | TARGET | R-A1 | R-T01 | LDIAM | Longest Diameter | 17 | mm | 17 | 17 | mm | RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 2 | EX01010 | TR | 90010 | 2 | TARGET | R-A1 |
| SUMDIAM | Sum of Diameter | 17 | mm | 17 | 17 | mm | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING |
|
| 3 | EX01010 | TR | 90010 | 3 | NON-TARGET | R-A1 | R-NT01 | TUMSTATE | Tumor State | PRESENT |
| PRESENT |
|
| RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 4 | EX01010 | TR | 90010 | 4 | NON-TARGET | R-A1 | R-NT02 | TUMSTATE | Tumor State | PRESENT |
| PRESENT |
|
| RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | SCREEN | 10 | SCREENING | 2010-01-02 | -2 | 5 | EX01010 | TR | 90010 | 5 | TARGET | R-R-A2 | R-T01 | LDIAM | Longest Diameter | 7 | mm | 7 | 7 | mm | RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 6 | EX01010 | TR | 90010 | 6 | TARGET | R-A2 |
| SUMDIAM | Sum of Diameter | 7 | mm | 7 | 7 | mm | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 7 | EX01010 | TR | 90010 | 7 | TARGET | R-A2 |
| ACNSD | Absolute Change From Nadir in Sum of Diameter | -10 | mm | -10 | -10 | mm | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 8 | EX01010 | TR | 90010 | 8 | TARGET | R-A2 |
| PCBSD | Percent Change From Baseline in Sum of Diameter | -59 | % | -59 | -59 | % | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 9 | EX01010 | TR | 90010 | 9 | TARGET | R-A2 |
| PCNSD | Percent Change From Nadir in Sum of Diameter | -59 | % | -59 | -59 | % | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 |
|
| 10 | EX01010 | TR | 90010 | 10 | NON-TARGET | R-A2 | R-NT01 | TUMSTATE | Tumor State | ABSENT |
| ABSENT |
|
| RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 11 | EX01010 | TR | 90010 | 11 | NON-TARGET | R-A2 | R-NT02 | TUMSTATE | Tumor State | ENLARGEMENT FROM NADIR |
| ENLARGEMENT FROM NADIR |
|
| RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 20 | WEEK 12 | 2010-03-29 | 85 | 12 | EX01010 | TR | 90010 | 12 | TARGET | R-A3 | R-T01 | LDIAM | Longest Diameter | 0 | mm | 0 | 0 | mm | RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | 13 | EX01010 | TR | 90010 | 13 | TARGET | R-A3 |
| SUMDIAM | Sum of Diameter | 0 | mm | 0 | 0 | mm | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 |
|
| 14 | EX01010 | TR | 90010 | 14 | TARGET | R-A3 |
| ACNSD | Absolute Change From Nadir in Sum of Diameter | -17 | mm | -17 | -17 | mm | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 |
|
| 15 | EX01010 | TR | 90010 | 15 | TARGET | R-A3 |
| PCBSD | Percent Change From Baseline in Sum of Diameter | -100 | % | -100 | -100 | % | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 |
|
| 16 | EX01010 | TR | 90010 | 16 | TARGET | R-A3 |
| PCNSD | Percent Change From Nadir in Sum of Diameter | -100 | % | -100 | -100 | % | RADIOL. INC. |
| INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 |
|
| 17 | EX01010 | TR | 90010 | 17 | NON-TARGET | R-A3 | R-NT01 | TUMSTATE | Tumor State | ABSENT |
| ABSENT |
|
| RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | 18 | EX01010 | TR | 90010 | 18 | NON-TARGET | R-A3 | R-NT02 | TUMSTATE | Tumor State | PRESENT |
| PRESENT |
|
| RADIOL. INC. | CT SCAN | INDEPENDENT ASSESSOR | RADIOLOGIST | TREATMENT | 30 | WEEK 24 | 2010-06-23 | 171 | |
|
...